My Quest Story – Pauline Chaves
NORTHAMPTON, MA / ACCESSWIRE / April 1, 2024 / Quest Diagnostics I started working for Quest Diagnostics in 2020, the...
COVID-19
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing...
How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together
Two Merck leaders share how their company is working to help protect communities from vaccine-preventable illnessesNORTHAMPTON, MA / ACCESSWIRE /...
NervGen Completes $23 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.Vancouver, British Columbia--(Newsfile Corp. -...
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Medical oncologist brings over 25 years of industry experience to lead Clinical Development StrategyBOSTON, March 28, 2024 (GLOBE NEWSWIRE) --...
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ETOCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech...
Lowell Farms Inc. Announces Audited Fourth Quarter and Fiscal Year 2023 Financial and Operational Results
SALINAS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis...
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza...
IMUNON Reports 2023 Financial Results and Provides Business Update
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Castle Biosciences Announces Updates to its Board of Directors
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced...
CorDx Receives Emergency Use Authorization (EUA) for 10-Min Flu A/B & COVID-19 Test
FDA Grants CorDx Emergency Use Authorization for Multi-Target Rapid Test for Flu A/B & COVID-19SAN DIEGO, CA / ACCESSWIRE /...
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing...
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpointsExpects two more Phase 3...
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources...
Dyadic to Attend Industry Events in April
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222Next-generation mRNA vaccine design offers the potential of...
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models...
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...